Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Aziyo Biologics ( (ELUT) ) has provided an update.
On February 3, 2025, Elutia Inc. announced a registered direct offering, selling 5,520,000 shares of Class A common stock and 480,000 prefunded warrants, aimed at raising approximately $15.0 million before expenses. The offering, which closed on February 4, 2025, is intended to provide working capital and support general corporate purposes, reflecting Elutia’s strategic financial planning. The company agreed to a lock-up period with its directors and officers, restricting the sale or transfer of securities for 90 days post-closing, and agreed with the Placement Agent to limit issuance of new shares during this period, indicating a focus on stabilizing its share price and market position.
More about Aziyo Biologics
YTD Price Performance: -18.82%
Average Trading Volume: 39,578
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $95.39M
See more insights into ELUT stock on TipRanks’ Stock Analysis page.